Elanco Animal Health Incorporated (ELAN) Stock Analysis & AI Equity Report

Drug Manufacturers - Specialty & Generic USD Explore free reports

Elanco Animal Health Incorporated (ELAN) overview

Elanco Animal Health Incorporated (ELAN) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 4,715m and operating profit of USD 15.0m; the year-end share price was 22.63 USD and market capitalisation was USD 11,247m. Elanco Animal Health Incorporated is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Elanco Animal Health Incorporated's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 6,547mFY 2025
Share price22.63 USDFY 2025 year end
RevenueUSD 4,715mFY 2025
Operating profitUSD 15.0mFY 2025
Net earningsUSD -232mFY 2025
Market capitalisationUSD 11,247mFY 2025 year end

About Elanco Animal Health Incorporated

Elanco develops and sells animal health products and services intended to prevent and treat disease in pets and farm animals. Its portfolio includes products for dogs, cats, cattle, poultry, swine and sheep, marketed under numerous brands in many countries. Customers and partners include farmers, pet owners and veterinarians. Its pet health products cover areas including parasite control, dermatology, vaccines and pain treatments.

Generate the Elanco Animal Health Incorporated report

Elanco Animal Health Incorporated is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Elanco Animal Health Incorporated and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Elanco Animal Health Incorporated

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.